Founded by Yale University scholars and their team returning to China, HebaBiz Biotech is committed to creating personalized, precise and improved solutions for the treatment of cancers and liver diseases, guided by clinical value and patients' needs, and systematically improving the quality of traditional Chinese medicines by the use of cutting-edge biotechnology. Both of our Beijing and Guangxi entities are "National High-tech Enterprises", and our Beijing entity is a "Zhongguancun Hi-Tech Technology Enterprise" and our Guangxi entity is a "Specialized, Excellent, Featured and Innovative Enterprise". HebaBiz Biotech has established a National & Local Joint Engineering Research Center for Anti-tumor Drug Development, systematic technology platforms for small-molecule drugs and innovative traditional Chinese medicines. HebaBiz Biotech has numerous international and domestic patented technologies, and seven new drug candidates in its pipeline under research and development, including China's Category 1.1 Anti-tumor Innovative Drug...
Numerous international and domestic patents
7 pipeline new drugs
And dozens of product approvals
Established a National Anti-tumor Research Center
3 Provincial Research Centers
1 Postdoctoral Research Workstation
68000+ square meters
Quality GMP production workshop
INNOVATIVE PIPELINE
Focusing on the clinical needs for anti-cancer and liver diseases, we have diversified product forms, mainly small-molecule chemical drugs and multi-molecule multi-target innovative Chinese medicines, which have synergistic effects with each other
Notes:
(1)An international multi-center, open-label Phase II/III clinical study is being carried out, and it is planned to be implemented in Taiwan, the United States and mainland China. Other solid tumor indications such as drug-resistant renal cancer, sarcoma cancer, bladder cancer, and liver cancer will be developed in the future.
(2) In animal model tests of pancreatic cancer and liver cancer, clevudine has shown obvious anti-tumor effects, and has synergistic effects with a variety of anti-tumor drugs already on the market and the company's new drugs troxacitabine and JP001. Patients with liver cancer caused by hepatitis B have better results. Preliminary studies have found multiple targets and biomarkers.
(3) Phase I-III trial approvals have been obtained; Phase I solid tumor research has been completed, and mechanism-related research has been supplemented, and new biomarkers/targets have been discovered; renal cancer single drug (including non-clear cell carcinoma) and pancreatic cancer combination are being developed. with Phase II-III studies.
(4) The IND application stage.
Important Events
Drag the mouse to slide